Key result
Familial hypercholesterolemia variants are linked to ~33% higher CAD risk independent of mean LDL-C.
Why the study?
It is unknown whether genetic testing for familial hypercholesterolemia variants provides additional coronary artery disease risk-stratifying information beyond longitudinal LDL-C measurements.
Does the presence of familial hypercholesterolemia genetic variants increase the risk of coronary artery disease independently of longitudinal LDL-C levels?
Case-Control (n=254,001)
Yes
Does the presence of familial hypercholesterolemia genetic variants increase the risk of coronary artery disease independently of longitudinal LDL-C levels?
Odds Ratio: 1.33 (95% CI 1.08–1.64)
Genetic testing for familial hypercholesterolemia variants provides additional risk stratification for coronary artery disease beyond what is captured by longitudinal LDL-C measurements.
FH variants may refine CAD risk stratification beyond LDL-C; hypothesis-generating and should not yet change practice.
Background: Familial hypercholesterolemia (FH) genetic variants confer risk for coronary artery disease independent of LDL-C (low-density lipoprotein cholesterol) when considering a single measurement. In real clinical settings, longitudinal LDL-C data are often available through the electronic health record. It is unknown whether genetic testing for FH variants provides additional risk-stratifying information once longitudinal LDL-C is considered. Methods: We used the extensive electronic health record data available through the Million Veteran Program to conduct a nested case-control study. The primary outcome was coronary artery disease, derived from electronic health record codes for acute myocardial infarction and coronary revascularization. Incidence density sampling was used to match case/control exposure windows, defined by the date of the first LDL-C measurement to the date of the first coronary artery disease code of the index case. Adjustments for the first, maximum, or mean LDL-C were analyzed. FH variants in LDLR , APOB , and PCSK9 (Proprotein convertase subtilisin/kexin type 9) were assessed by custom genotype array. Results: In a cohort of 23 091 predominantly prevalent cases at enrollment and 230 910 matched controls, FH variant carriers had an increased risk for coronary artery disease (odds ratio [OR], 1.53 [95% CI, 1.24–1.89]). Adjusting for mean LDL-C led to the greatest attenuation of the risk estimate, but significant risk remained (odds ratio, 1.33 [95% CI, 1.08–1.64]). The degree of attenuation was not affected by the number and the spread of LDL-C measures available. Conclusions: The risk associated with carrying an FH variant cannot be fully captured by the LDL-C data available in the electronic health record, even when considering multiple LDL-C measurements spanning more than a decade.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a case-control in Coronary artery disease (n=254,001). Familial hypercholesterolemia (FH) genetic variants vs. Non-carriers was evaluated on Coronary artery disease, derived from electronic health record codes for acute myocardial infarction and coronary revascularization (OR 1.33, 95% CI 1.08-1.64). Carrying a familial hypercholesterolemia genetic variant was associated with an increased risk of coronary artery disease independent of longitudinal mean LDL-C levels (OR 1.33; 95% CI 1.08-1.64).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: